John Courtney, BS, PTA Physical Medicine & Rehabilitation Medicare: Not Enrolled in Medicare Practice Location: 4140 Old Washington Rd, Waldorf, MD 20602 Phone: 301-645-2813 |
Dr. David Antonio Rodriguez, D.O. Physical Medicine & Rehabilitation Medicare: Accepting Medicare Assignments Practice Location: 12070 Old Line Ctr Ste 205, Waldorf, MD 20602 Phone: 301-659-0003 |
Mariam Razaq, D.O. Physical Medicine & Rehabilitation Medicare: Accepting Medicare Assignments Practice Location: 601 Post Office Rd Ste 2a, Waldorf, MD 20602 Phone: 240-754-7954 Fax: 240-754-7958 |
Dr. Matthew S. Roh, M.D. Physical Medicine & Rehabilitation Medicare: Accepting Medicare Assignments Practice Location: 11637 Terrace Dr Ste 101, Waldorf, MD 20602 Phone: 240-629-3939 Fax: 240-629-3940 |
News Archive
The first two research projects supported by the Pfizer-FRSQ Innovation Fund will investigate differences in the genetic code for inflammatory bowel disease and metastatic colorectal cancer. This research could lead to improved diagnosis and the development of individualized treatments for these diseases. These innovative projects are marshalling multidisciplinary teams of seasoned researchers from major Quebec research institutions.
Medtronic, Inc. today reported financial results for the third quarter of fiscal year 2010, which ended January 29, 2010.
A recent computational study from India implicated a dysregulated vitamin D pathway in the pathobiology of the infection with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – and opened the door for experimental validation of these observations.
ThromboGenics NV, a biopharmaceutical company focused on developing innovative ophthalmic medicines, announces today that it has entered into an agreement with Alcon (a division of Novartis), the global leader in eyecare, for the commercialization of ocriplasmin in all markets outside the U.S.
The National Institutes of Health has announced the recipients of the 2011 Transformative Research Award Projects. This innovative research program was established in 2009 to support exceptionally innovative, high risk, original and/or unconventional research projects, and is supported by the NIH Common Fund.
› Verified 7 days ago